[1]
|
A. Park, “In 40 Years of Cancer Research, How Far Have We Come?” Time Heatland, 2011.
http://healthland.time.com/2011/09/21/cancer-researchs-40th-anniversary-how-far-have-we-come/#more-43198
|
[2]
|
G. Morgan, R. Ward and M. Barton, “The Contribution of Cytotoxic Chemotherapy to 5-Year Survival in Adult Malignancies,” Journal of Clinical Oncology, Vol. 16, No. 8, 2004, pp. 549-560.
doi:10.1016/j.clon.2004.06.007
|
[3]
|
F. R. Lichtenberg, “Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France,” Pharmacoeconomics, Vol. 30, No. 3, 2012, pp. 197-211.
doi:10.2165/11587150-000000000-00000
|
[4]
|
R. Li and J. A. Stafford, “Kinase Inhibitor Drugs,” 1st Edition, John Wiley & Sons, Hoboken, 2009.
doi:10.1002/9780470524961
|
[5]
|
D. R. Robinson, Y. Wu and S. Lin, “The Protein Tyrosine Kinase Family of the Human Genome,” Oncogene, Vol. 19, No. 49, 2000, pp. 5548-5557.
doi:10.1038/sj.onc.1203957
|
[6]
|
J. Zhang, P. L. Yang and N. S. Gray, “Targeting Cancer with Small Molecule Kinase Inhibitors,” Nature Reviews Cancer, Vol. 9, No. 1, 2009, pp. 28-39.
doi:10.1038/nrc2559
|
[7]
|
B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann and N. B. Lydon, “Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells,” Nature Medicine, Vol. 2, No. 5, 1996, pp. 561-566.
doi:10.1038/nm0596-561
|
[8]
|
R. Capdeville, E. Buchdunger, J. Zimmermann and A. Matter, “Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug,” Nature Reviews Drug Discovery, Vol. 1, No. 7, 2002, pp. 493-502.
doi:10.1038/nrd839
|
[9]
|
M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott and A. J. Zigler, “Inhibition of c-Kit Receptor Tyrosine Kinase Activity by STI 571, a Selective Tyrosine Kinase Inhibitor,” Blood, Vol. 96, No. 3, 2000, pp. 925-932.
|
[10]
|
C. M. Christensen, “The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail,” Harvard Business School Press, Cambridge, 1997.
|
[11]
|
J. P. Overington, B. Al-Lazikani and A. L. Hopkins, “How Many Drug Targets Are There?” Nature Reviews Drug Discovery, Vol. 5, No. 12, 2006, pp. 993-996.
doi:10.1038/nrd2199
|
[12]
|
S. Frantz, “Drug Discovery: Playing Dirty,” Nature, Vol. 437, No. 7061, 2005, pp. 942-943.
doi:10.1038/437942a
|
[13]
|
A. L. Hopkins, “Drug Discovery: Predicting Promiscuity,” Nature, Vol. 462, No. 7270, 2009, pp. 167-168.
doi:10.1038/462167a
|
[14]
|
J. Vesely, L. Havlicek, M. Strnad, J. J. Blow, A. Donella-Deana, L. Pinna, D. S. Letham, J. Kato, L. Detivaud and S. LeClerc, “Inhibition of Cyclin-Dependent Kinases by Purine Analogues,” European Journal of Biochemistry, Vol. 224, No. 2, 1994, pp. 771-786.
doi:10.1111/j.1432-1033.1994.00771.x
|
[15]
|
L. Meijer and E. Raymond, “Roscovitine and Other Purines as Kinase Inhibitors, from Starfish Oocytes to Clinical Trials,” Accounts of Chemical Research, Vol. 36, No. 6, 2003, pp. 417-425. doi:10.1021/ar0201198
|
[16]
|
R. Jorda, L. Havlí?ek, I. W. McNae, M. D. Walkinshaw, J. Voller, S A. turc, J. Navratilova, M. Kuzma, M. Mistrik, J. Bartek, M. Strnad and V. Krystof, “Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity,” Journal of Medicinal Chemistry, Vol. 54, No. 8, 2011, pp. 2980-2993.
doi:10.1021/jm200064p
|
[17]
|
M. F. Bra?a, M. Cacho, M. L. Garc?′a, E. P. Mayoral, B. Lo’pez, B. de Pascual-Teresa, A. Ramos, N. Acero, F. Llinares, D. Mu?oz-Mingarro, O. Lozach and L. Meijer, “Pyrazolo[3,4-c]pyridazines as Novel and Selective Inhibitors of Cyclin-Dependent Kinases,” Journal of Medicinal Chemistry, Vol. 48, No. 22, 2005, pp. 6843-6854.
doi:10.1021/jm058013g
|
[18]
|
F. A. Yassin, “Synthesis, Reactions and Biological Activity of 2-Substituted 3-Cyano-4,6-Dimethylpyridine Derivatives,” Chemistry of Heterocyclic Compounds, Vol. 45, No. 1, 2009, pp. 35-41. doi:10.1007/s10593-009-0222-x
|
[19]
|
A. M. Hussein, E. A. Ishak, A. A. Atalla, S. Abdel Hafiz and M. H. Elnagdi, “Phenylacetone as Building Blocks in Heterocyclic Synthesis: Synthesis of PolyfunctionallySubstituted Pyridines, and Fused Pyridines,” Phosphorus, Sulfur, and Silicon and the Related Elements, Vol. 182, No. 12, 2007, pp. 2897-2917.
doi:10.1080/10426500701542858
|
[20]
|
U. Schulze-Gahmen, H. L. De Bondt and S. Kim, “HighResolution Crystal Structures of Human CyclinDependent Kinase 2 with and without ATP:? Bound Waters and Natural Ligand as Guides for Inhibitor Design,” Journal of Medicinal Chemistry, Vol. 39, No. 23, 1996, pp. 4540-4546. doi:10.1021/jm960402a
|
[21]
|
C. E. Arris, F. T. Boyle, A. H. Calvert, N. J. Curtin, J. A. Endicott, E. F. Garman, A. E. Gibson, B. T. Golding, S. Grant, R. J. Griffin, P. Jewsbury, L. N. Johnson, A. M. Lawrie, D. R. Newell, M. E. Noble, E. A. Sausville, R. Schultz and W. Yu, “Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles,” Journal of Medicinal Chemistry, Vol. 43, No. 15, 2000, 2797-2804. doi:10.1021/jm990628o
|
[22]
|
P. Furet, “X-Ray Crystallographic Studies of CDK2, a Basis for Cyclin-Dependent Kinase Inhibitor Design in Anti-Cancer Drug Research,” Current Medicinal Chemistry Anti-Cancer Agents, Vol. 3, No. 1, 2003, pp. 15-23.
doi:10.2174/1568011033353515
|